Home ›
Multiple Myeloma Trials ›
NCT05344833
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)
Trial Details
NCT ID NCT05344833 Phase PHASE2
Sponsor University of Illinois Chicago
Status RECRUITING
Cancer Type Multiple Myeloma
Interventions Locations (sample) Chicago, Illinois, United States|41.85003,-87.65005 Salt Lake City, Utah, United States|40.76078,-111.89105
Key Eligibility Criteria
Age \> 18 years Patients must have a confirmed diagnosis of multiple myeloma according to IMWG criteria. Patients with smoldering multiple myeloma, or plasma cell … R-ISS stage 1, 2 or 3 at diagnosis. If stage at diagnosis is not known, patient may be enrolled if the intent is to treat with post -ASCT maintenan… Received up to or less than 2 lines of therapy prior to ASCT (as long as they did not meet IMWG refractory disease for CD38 monoclonal antibody or … For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Multiple Myeloma Trials on Trialify →